In a cohort of 292 patients with non-small-cell lung cancer, a lower SREBF1 expression in tumors than in adjacent nontumor tissue correlated with overall better survival, specifically in patients with adenocarcinoma at stage I. Thus, SREBF1 expression can be considered as a prognostic factor for better patient overall survival. The gene discussed is SREBF1; the disease is adenocarcinoma.